Here are the 8-K filings from Bio Essence Corp (BIOE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow BIOE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIOE filings page.
Bio Essence Corp. (BIOE) reports that shareholders elected Xiying (Thea) Zhang and Geoff Fellows as directors effective October 19, 2026. Shareholders also amended the bylaws, raising the permitted maximum from three directors to ten while retaining a minimum of one. Holders of 63.92% of issued and outstanding common stock signed the written consent. Zhang has more than 15 years of experience in operations, manufacturing strategy and product commercialization; Fellows is chief executive officer of Embarcadero Accessible Multi-Family Office and has more than three decades of experience in finance, operations, compliance and governance.
Bio Essence Corp. entered into an asset purchase agreement to acquire the MediFlow AI software platform (formerly AcuVital) from Zhituo Software Co., Limited. The purchase price is $3,500,000, to be paid entirely in restricted common stock.
The board determined that 7,000,000 shares of common stock valued at $0.50 per share will satisfy the price. Zhituo subsequently assigned its right to receive these shares to its three principals, Dangwei Zhu, Jiahui Zhang, and Xiaoqiang Cai, with Bio Essence’s consent. The share issuances to these individuals were deemed effective on or about May 19, 2026, completing the transaction.
Bio Essence Corp. entered into an Asset Purchase Agreement to acquire the MediFlow AI software platform (formerly AcuVital) from Zhituo Software Co., Limited. The purchase price is equity consideration in restricted common stock valued at $3,500,000, with fair market value and share count to be approved by the Board.
The deal transfers all rights, title, and interest in the MediFlow AI platform, including source code, architecture, and related data, while excluding any equity interest in the seller. Closing is scheduled on or before 45 days from signing, subject to conditions precedent, and the shares will be issued under securities law exemptions and treated as restricted securities.